Eli Lilly (LLY)
(Delayed Data from NYSE)
$923.71 USD
-11.31 (-1.21%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $925.05 +1.34 (0.15%) 7:58 PM ET
1-Strong Buy of 5 1
F Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
LLY 923.71 -11.31(-1.21%)
Will LLY be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for LLY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for LLY
Roche Gets FDA Approval for Subcutaneous Formulation of Tecentriq
NVO Oral Obesity Pill Tops Wegovy; LLY, VKTX, GPCR Stocks Rise
LLY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Novo Nordisk Stock Rises as Oral Obesity Pill Outshines Wegovy
FDA Grants Label Expansion to J&J's Tremfya in Ulcerative Colitis
Boost Your Portfolio's Health With These 4 Large-Cap Drug Stocks
Other News for LLY
Executive reshuffles: LLY, S and RY Companies in focus
FDA Approves Lilly's EBGLYSS? (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis
Eli Lilly wins buy as Citi resumes coverage on obesity prospects
Eli Lilly announces FDA approval of EBGLYSS
Eli Lilly price target raised by $50 at JPMorgan, here's why